This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter W. Heald, MD

Arch Dermatol. 1993;129(6):763-765.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

On reading the article by Mostow et al¹ in this issue of the ARCHIVES, it becomes apparent that several forces that will control our management of patients will converge on the issue of interferon for cutaneous T-cell lymphoma (CTCL). The New York Times (January 18, 1993:1) headline "New Standard for Drug Makers: Proving the Cure Is Worth the Cost" reflected Washington's interest in this and similar studies. Now, with an office in the White House, Hillary Clinton will take the lead in defining the integration of new therapies into the administration's health care policy. Prodding on this collision of interests is the revolution in T-cell biology that is bringing a hailstorm of biological insights into T-cell lymphoma faster than anyone can catch them or consider who should pay for them. These forces will encounter each other over the next few months, and therapy assessment will be a major issue. . . . [Full Text PDF of this Article]

Author Affiliations
Department of Dermatology Yale University School of Medicine 500 LCI 333 Cedar St New Haven, CT 06510

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?